The short answer
Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, at 711.9 Da. It acts at the ghrelin receptor and was described by Raun and colleagues in 1998 as the first selective growth hormone secretagogue. Selective here means it released GH without the cortisol and prolactin effects of earlier compounds.
Key facts
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Residues
- 5, C-terminal amide
- Molecular weight
- 711.9 Da
- Formula
- C38H49N9O5
- CAS number
- 170851-70-4
- PubChem CID
- 9831659
- Development code
- NNC 26-0161 (Novo Nordisk)
- Target
- Ghrelin receptor (GHS-R1a)
What selective meant
Raun and colleagues titled their 1998 paper in the European Journal of Endocrinology 'Ipamorelin, the first selective growth hormone secretagogue'. The selectivity claim is specific: earlier secretagogues released GH but also raised cortisol and prolactin, which confounds both research and any therapeutic use. Ipamorelin was reported to release GH without those accompanying effects.
The unusual residues
Only one of its five residues is an ordinary L-amino acid. Position 1 is α-aminoisobutyric acid (Aib), a non-proteinogenic residue with a quaternary alpha carbon. Positions 3 and 4 are D-amino acids: D-2-naphthylalanine and D-phenylalanine. Position 2 is histidine and position 5 lysine, with a C-terminal amide. This is a heavily engineered molecule rather than a natural sequence.
Research material referenced
CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested
Why Aib appears here and in semaglutide
This is a real cross-connection. Aib's quaternary alpha carbon makes adjacent bonds poor substrates for peptidases, which is why semaglutide carries Aib at position 8 to block DPP-4. Two entirely unrelated peptides, thirty years apart, reach for the same residue to solve the same problem: protease resistance in a short peptide.
What D-amino acids do
Proteases evolved to cleave L-amino acid backbones and generally cannot process D-residues. Two D-residues in a five-residue peptide makes most of it enzymatically inaccessible. Combined with Aib and the C-terminal amide, which blocks carboxypeptidases, nearly every position is protected. The peptide is short because it does not need length to survive.
The ghrelin receptor
Ipamorelin acts at the growth hormone secretagogue receptor GHS-R1a, whose endogenous ligand is ghrelin. That is a different pathway from CJC-1295's, which acts at the GHRH receptor. Both converge on pituitary GH release, which is the basis for studying them together.
Regulatory position
Ipamorelin holds no marketing authorisation from the MHRA, EMA or FDA. Growth hormone secretagogues are prohibited in sport under the WADA list. It is supplied here for laboratory research only.
Frequently asked questions
What does selective mean for ipamorelin?
That it released GH without the cortisol and prolactin increases seen with earlier secretagogues, the specific claim in Raun's 1998 paper title.
What is Aib?
α-aminoisobutyric acid, a non-proteinogenic residue whose quaternary alpha carbon blocks peptidase access. It is the same residue semaglutide uses to block DPP-4.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedRaun K et al., Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998 (PMID 9849822)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Ipamorelin (CID 9831659)pubchem.ncbi.nlm.nih.gov
- PubMedMüller TD et al., Ghrelin. Molecular Metabolism 2015 (PMID 26042199)pubmed.ncbi.nlm.nih.gov
- PubMedTeichman et al., Prolonged stimulation of GH & IGF-I by CJC-1295. J Clin Endocrinol Metab 2006 (PMID 16352683)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 / mod GRF (1-29) (CID 56841945)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 with DAC (CID 91971820)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More CJC-1295 & Ipamorelin articles
- How CJC-1295 Works as a GHRH AnalogueCJC-1295 agonises the GHRH receptor on pituitary somatotrophs. Why the substitutions matter and what continuous versus pulsatile stimulation implies.
- Why These Two Are Studied TogetherTwo receptors, one output. The mechanistic rationale for pairing a GHRH analogue with a ghrelin receptor agonist - and what would be needed to test it.
- What the Published Literature ContainsTwo human pharmacokinetic studies from 2006, a 1998 selectivity paper, and comparatively little else. A small but unusually clinical evidence base.
- Storage and Reconstitution for Both CompoundsTwo peptides differing fivefold in mass, stored together but not identical. Why the DAC form's maleimide is the one genuinely reactive feature here.
- What Is CJC-1295? The Two Forms and Their MassesCJC-1295 is a GHRH analogue based on GRF(1-29) with four stabilising substitutions. Two forms exist at different masses, and they are routinely conflated.